Founded in 1897 in Switzerland, Lonza Group AG has developed into one of the world’s leading contract development and manufacturing organizations dedicated to the healthcare industry. Headquartered in Basel, Switzerland, the company supports pharmaceutical and biotechnology customers across the full development and manufacturing pathway, with established capabilities in biologics, small molecules, and cell and gene technologies. Recognized as the first and original CDMO, Lonza combines scientific depth with large-scale manufacturing expertise and a global operating platform. In 2025, the company reported sales of CHF 6.5 billion and described its organization as a team of around 20,000 colleagues across five continents.
Updated 2026-03-19